BioMar Group A/S
Denmark · DK0064867972 · reports in DKK · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue −0.5% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned 22% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 29% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in DKK.
DKK 16.5B
revenue
6.8%
operating margin
DKK 714M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | DKK 17.9B | DKK 17.9B | DKK 16.6B | DKK 16.5B |
| Operating profit | DKK 602M | DKK 860M | DKK 1.1B | DKK 1.1B |
| Net profit to shareholders | DKK 532M | DKK 461M | DKK 675M | DKK 714M |
| Earnings per share | n/a | n/a | DKK 6753.00 | DKK 7143.00 |
| Cash from operations | DKK 299M | DKK 665M | DKK 1.6B | DKK 1.6B |
| Capital spending | DKK 228M | DKK 201M | DKK 188M | DKK 260M |
| Cash | DKK 299M | DKK 184M | DKK 434M | DKK 632M |
| Total assets | DKK 11.7B | DKK 11.2B | DKK 11.3B | DKK 11.1B |
| Equity | DKK 3.2B | DKK 3.1B | DKK 3.6B | DKK 3.2B |
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.